Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Trigger factors for prophylactic platelet transfusion

P J Ancliff1, S J Machin

  • 1Department of Haematology, University College Hospital, London, UK.

Blood Reviews
|February 9, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A performance evaluation of a novel human recombinant tissue factor prothrombin time reagent (Revohem<sup>™</sup> PT).

International journal of laboratory hematology·2017
Same author

ICSH recommendations for modified and alternate methods measuring the erythrocyte sedimentation rate.

International journal of laboratory hematology·2017
Same author

Rivaroxaban limits complement activation compared with warfarin in antiphospholipid syndrome patients with venous thromboembolism.

Journal of thrombosis and haemostasis : JTH·2016
Same author

Recombinant Alpha 2A Interferon-An Effective Maintenance Agent in Essential Thrombocythaemia.

Leukemia & lymphoma·2016
Same author

Interactions between rivaroxaban and antiphospholipid antibodies in thrombotic antiphospholipid syndrome.

Journal of thrombosis and haemostasis : JTH·2015
Same author

ICSH recommendations for the standardization of nomenclature and grading of peripheral blood cell morphological features.

International journal of laboratory hematology·2015
Same journal

Treating large B-cell lymphoma: Current strategies and unmet needs across community and academic settings.

Blood reviews·2026
Same journal

MRD in multiple myeloma: Moving from "minimal" to "measurable".

Blood reviews·2026
Same journal

PRISMA-based systematic review on iron stores in repeat blood donors.

Blood reviews·2026
Same journal

Artificial intelligence applications in thrombotic thrombocytopenic Purpura: A systematic review of diagnostic, risk stratification, and prognostic models.

Blood reviews·2026
Same journal

Antibacterial, antifungal and antiviral prophylaxis and vaccination strategies in adult patients with acute myeloid and promyelocytic leukemia: An expert panel consensus from the GIMEMA group.

Blood reviews·2026
Same journal

The Lebanese national patient blood management guidelines: A new page in the medical practice.

Blood reviews·2026
See all related articles

A platelet transfusion threshold of 10x10(9)/L is safe for stable patients, challenging older guidelines. This evidence-based approach reduces donor exposure and costs.

Area of Science:

  • Hematology
  • Transfusion Medicine

Background:

  • Current prophylactic platelet transfusion guidelines, often based on outdated data from the 1950s, recommend higher thresholds.
  • Recent clinical practice has seen a trend towards lower transfusion thresholds, with some institutions adopting levels as low as 5x10(9)/L.

Observation:

  • This study re-evaluated recent data concerning prophylactic platelet transfusion triggers.
  • The research focused on determining a safe and effective platelet count threshold for transfusion in stable patients.

Findings:

  • A threshold of 10x10(9)/L for prophylactic platelet transfusion is identified as safe for stable patients.
  • Higher platelet levels are deemed necessary only for specific clinical situations.

Implications:

Related Experiment Videos

  • Implementing a 10x10(9)/L threshold can significantly decrease donor exposure and associated costs.
  • This revised threshold may also reduce the incidence of donor alloimmunization.
  • The study highlights a need for more prospective, controlled clinical trials to further refine transfusion guidelines.